ConductScience.org, home

Paper12410643

Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.

Fischer K and 6 others. Haemophilia, 2002. Cited by 130 papers, by iCite.

Cite this record

ConductScience Library. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Papers, record 12410643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12410643

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.
PubMed
Journal
Haemophilia
PubMed
Year
2002
PubMed
Publication types
Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
130
iCite
Relative citation ratio, by iCite
4.32
iCite
Revised in PubMed
2019-11-06
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fischer KK
2Astermark JJ
3van der Bom JGJ G
4Ljung RR
5Berntorp EE
6Grobbee DED E
7van den Berg HMH M

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Factor IXMajor topic
Factor VIIIMajor topic
Hemophilia AMajor topic
Hemophilia BMajor topic
Adolescent
Adult
Child
Dose-Response Relationship, Drug
Follow-Up Studies
Hemarthrosis
Humans
Male
Quality of Life
Treatment Outcome

Source PubMed

Download CSV of topics

Cited by29

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 130 citations.

PMIDTitleJournalYearIn PapersSource
42983703Long-term risk factors for hemophilic arthropathy in patients with severe hemophilia A: a 36-year retrospective cohort study.BMC Musculoskelet Disord2026https://conductscience.org/library/papers/42983703PubMed
41087175[Chinese guidelines on the treatment of hemophilia (2025)].Zhonghua Xue Ye Xue Za Zhi2025https://conductscience.org/library/papers/41087175PubMed
39565566Evaluating the Effectiveness of Prophylactic Strategies for Hemophilia A Management: A Real-World, Longitudinal Observational Study.Drugs Real World Outcomes2024https://conductscience.org/library/papers/39565566PubMed
36859289Successful treatment of Henoch-Schönlein purpura-associated hematochezia in a child with hemophilia A: a case report.BMC Pediatr2023https://conductscience.org/library/papers/36859289PubMed
36428936A Novel Deletion Mutation of the F8 Gene for Hemophilia A.Diagnostics (Basel)2022https://conductscience.org/library/papers/36428936PubMed
35030189Effects of replacement therapies with clotting factors in patients with hemophilia: A systematic review and meta-analysis.PLoS One2022https://conductscience.org/library/papers/35030189PubMed
34703973Magnetic resonance imaging in boys with severe hemophilia A: Serial and end-of-study findings from the Canadian Hemophilia Primary Prophylaxis Study.Res Pract Thromb Haemost2021https://conductscience.org/library/papers/34703973PubMed
34168126Haemophilia.Nat Rev Dis Primers2021https://conductscience.org/library/papers/34168126PubMed
34040833Adherence to prophylaxis in adolescents and young adults with severe haemophilia A, a qualitative study with patients.Health Psychol Behav Med2018https://conductscience.org/library/papers/34040833PubMed
32467138Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies.Haematologica2020https://conductscience.org/library/papers/32467138PubMed
32196903FVIII activity following FVIII protein infusion or FVIII gene transfer predicts the bleeding risk in hemophilia A rats.J Thromb Haemost2020https://conductscience.org/library/papers/32196903PubMed
31259302HAEMOcare: The First International Epidemiological Study Measuring Burden of Hemophilia in Developing Countries.TH Open2019https://conductscience.org/library/papers/31259302PubMed
29735454[Prophylactic treatment with low- and intermediate-dose factor VIII in children with severe hemophilia A: comprehensive evaluation of joint outcomes and correlation analysis].Nan Fang Yi Ke Da Xue Xue Bao2018https://conductscience.org/library/papers/29735454PubMed
26403578Scoring haemophilic arthropathy on X-rays: improving inter- and intra-observer reliability and agreement using a consensus atlas.Eur Radiol2016https://conductscience.org/library/papers/26403578PubMed
25177652Endodontic management of a haemophilic patient- a clinical perspective.J Clin Diagn Res2014https://conductscience.org/library/papers/25177652PubMed
25074524Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future.Blood Transfus2014https://conductscience.org/library/papers/25074524PubMed
24895637Psychometric properties of the Greek Haem-A-QoL for measuring quality of life in Greek haemophilia patients.Biomed Res Int2014https://conductscience.org/library/papers/24895637PubMed
23908669Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea.Korean J Pediatr2013https://conductscience.org/library/papers/23908669PubMed
23777770Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.Blood2013https://conductscience.org/library/papers/23777770PubMed
23149144Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal?Blood Transfus2013https://conductscience.org/library/papers/23149144PubMed

See all 29 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/12410643

GET https://conductscience.org/api/papers/v1/12410643/cited_by?page=2